Devyser Diagnostics AB (DVYSR) - Total Liabilities
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has total liabilities worth Skr112.20 Million SEK (≈ $12.07 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Devyser Diagnostics AB - Total Liabilities Trend (2018–2025)
This chart illustrates how Devyser Diagnostics AB's total liabilities have evolved over time, based on quarterly financial data. See Devyser Diagnostics AB (DVYSR) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Devyser Diagnostics AB Competitors by Total Liabilities
The table below lists competitors of Devyser Diagnostics AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Samjin Pharm
KO:005500
|
Korea | ₩184.63 Billion |
|
Li Peng Enterprise Co Ltd
TW:1447
|
Taiwan | NT$7.65 Billion |
|
Zhejiang Zone King Environmental Sci&Tech Co Ltd
SHG:688701
|
China | CN¥317.25 Million |
|
Hwashin Precision Engineering Co. Ltd
KQ:126640
|
Korea | ₩108.61 Billion |
|
Shane Global Holding Inc
TW:8482
|
Taiwan | NT$1.49 Billion |
|
BioInvent International AB
ST:BINV
|
Sweden | Skr105.93 Million |
|
Alkim Kagit Sanayi ve Ticaret AS
IS:ALKA
|
Turkey | TL103.45 Million |
|
Shriram Properties Limited
NSE:SHRIRAMPPS
|
India | Rs27.51 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Devyser Diagnostics AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Devyser Diagnostics AB (DVYSR) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.90 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.24 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Devyser Diagnostics AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Devyser Diagnostics AB (2018–2025)
The table below shows the annual total liabilities of Devyser Diagnostics AB from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr115.40 Million ≈ $12.42 Million |
-7.53% |
| 2024-12-31 | Skr124.80 Million ≈ $13.43 Million |
-0.16% |
| 2023-12-31 | Skr125.00 Million ≈ $13.45 Million |
+80.66% |
| 2022-12-31 | Skr69.19 Million ≈ $7.45 Million |
+72.19% |
| 2021-12-31 | Skr40.18 Million ≈ $4.32 Million |
-7.80% |
| 2020-12-31 | Skr43.58 Million ≈ $4.69 Million |
+18.78% |
| 2019-12-31 | Skr36.69 Million ≈ $3.95 Million |
+101.02% |
| 2018-12-31 | Skr18.25 Million ≈ $1.96 Million |
-- |
About Devyser Diagnostics AB
Devyser Diagnostics AB (publ) provides diagnostic kits and advanced analysis services for clinical genetics and post-transplantation laboratories in Sweden, rest of Europe, the Middle East, and Africa. It offers kits and reagents, such as post-transplantation, thalassemia, fetal RHD screening NIPT, Cystic fibrosis cardiovascular diseases, male infertility, rapid aneuploidy analysis, accessories, … Read more